Asset Details
Do you wish to reserve the book?
Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer
Do you wish to request the book?
Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer
2017
Overview
Background:
Activating mutations in KRAS have been suggested as potential predictive and prognostic biomarkers. However, the prognostic impact of specific point mutations remains less clear. This study assessed the prognostic impact of specific KRAS mutations on survival for patients with colorectal cancer.
Methods:
Retrospective review of patients KRAS typed for advanced and recurrent colorectal cancer between 2010 and 2015 in a UK Cancer Network.
Results:
We evaluated the impact of KRAS genotype in 392 patients. Mutated KRAS was detected in 42.9% of tumours. KRAS mutations were more common in moderate
vs
well-differentiated tumours. On multivariate analysis, primary tumour T stage (HR 2.77 (1.54–4.98),
P
=0.001), N stage (HR 1.51 (1.01–2.26),
P
=0.04), curative intent surgery (HR 0.51 (0.34–0.76),
P
=0.001), tumour grade (HR 0.44 (0.30–0.65),
P
=0.001) and KRAS mutation (1.54 (1.23–2.12),
P
=0.005) were all predictive of overall survival. Patients with KRAS codon 12 mutations had worse overall survival (HR 1.76 (95% CI 1.27–2.43),
P
=0.001). Among the five most common codon 12 mutations, only p.G12C (HR 2.21 (1.15–4.25),
P
=0.01) and p.G12V (HR 1.69 (1.08–2.62),
P
=0.02) were predictive of overall survival.
Conclusions:
For patients with colorectal cancer, p.G12C and p.G12V mutations in codon 12 were independently associated with worse overall survival after diagnosis.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Adult
/ Aged
/ Biomarkers, Tumor - genetics
/ Biomedical and Life Sciences
/ Colorectal Neoplasms - genetics
/ Colorectal Neoplasms - mortality
/ Colorectal Neoplasms - pathology
/ Disease
/ Female
/ Genotype
/ Humans
/ Male
/ Mutation
/ Neoplasm Recurrence, Local - genetics
/ Neoplasm Recurrence, Local - mortality
/ Neoplasm Recurrence, Local - pathology
/ Oncology
/ Proto-Oncogene Proteins p21(ras) - genetics
/ Surgery
/ Tumors
